Formycon Ag · XETR:FYB
Formycon — Investor Presentation (April 2025)
22 slides from Formycon's investor presentation, April 2025
Slide 1: Formycon AG – The Biosimilar Experts
Formycon AG The Biosimilar Experts April 2025
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial si
Slide 3: Skillset and mindset are our key ingredients
Skillset and mindset are our key ingredients Pure Play Biosimilar 250 employees from more Combining high professional Formycon's pipeline Company – established 2012 than 30 different countries. expertise in biopharma- includes three approved in Munich, Germany. ceutical development with biosimilars,
Slide 4: We are acting along a clear mission
We are acting along a clear mission Biosimilars open up enormous opportunities Contributing to ease Improving the financial strains on the patient access to vital world’s healthcare systems medicines 4 Formycon FormyconAG AG– //The TheBiosimilar BiosimilarExperts Experts
Slide 5: Maximizing our assets along a clear path
Laser focus on pipeline execution and expansion Maximizing our assets along a clear path 2024 2025 Important year with Further Sustainable many operational transformation profitability milestones into a commercial with continuous successfully company with pipeline achieved two products on growth key
Slide 6: Many important Milestones achieved over the last months
Many important Milestones achieved over the last months ** *SDAX in December 2024 & TecDax in January 2025 ** in February 2025 6 Formycon AG Formycon AG // The Biosimilar Experts
Slide 7: Huge Biosimilar target opportunities
Huge Biosimilar target opportunities > 40 Blockbuster drugs with an expected global sales volume of more than 200 USD billion will lose their exclusivity in the coming years, creating huge opportunities for Biosimilars Year Number of blockbuster drugs losing exclusivity Cumulative global annual peak
Slide 8: The Biosimilar market develops very dynamically
The Biosimilar market develops very dynamically Global Biosimilar Sales 2016 – 2030 USD billion* 74.0 2015 – 2021 2021 – 2025 RoW CAGR 39% RoW CAGR 16% US CAGR 97% US CAGR 26% Europe CAGR 48% Europe CAGR 8% Biosimilars is the fastest growing segment ● ROW 32.9 in Pharma. The US market ● US ● EUROPE
Slide 9: Biosimilar development – high probability of success
Biosimilar development – high probability of success The probability of success for a Biosimilar is continuously high over the course of development1. This is different for innovative drug developments: Here, on average, only one in twelve innovative drugs makes it from the preclinical stage to appr
Slide 10: Full value chain covered in successful hybrid model
Full value chain covered in successful hybrid model With our team of highly experienced scientists and regulatory affairs experts, Formycon covers a large part of the Biosimilar development value chain in-house. For the areas of manufacturing and commercialization, we rely on well trusted long-term
Slide 11: Strong maturing and growing pipeline
Strong maturing and growing pipeline Diversified portfolio of commercial, late and mid stage programs Lucentis® 50% Further approvals Ophthalmology $1,2bn US* ex-US MENA (Genentech Inc.) owned and launches 2022 Stelara® Fully Launches in Immunology $10.4bn (Johnson & Johnson) owned Canada and UK 202
Slide 12: Lucentis Biosimilar FYB201 – Strong Presence across the World
Lucentis® Biosimilar FYB201 – Strong Presence across the World FYB201/ranibizumab so far launched in 20 Countries Growth drivers ● Introduction of Prefilled Syringe in European Markets ● Entering additional Markets globally ● Further Lifecycle Management Optimizations ● Prepare for strong Re-entry i
Slide 13: Stelara Biosimilar FYB202 – first Patients treated with Otulfi
Stelara® Biosimilar FYB202 – first Patients treated with Otulfi® FYB202/ustekinumab launched in the US and in Europe in Q1 Growth drivers ● Build Momentum in US and EU ● Add. Launches globally, e.g. CA, UK ● Further LCM Optimizations Stelara® is a registered trademark of Johnson & Johnson Otulfi® is
Slide 14: FYB202 – Stelara Biosimilar launched in the U.S. and the EU
FYB202 – Stelara® Biosimilar launched in the U.S. and the EU Approved Targeted Reference Indications Psoriasis (Arthritis), Crohn’s Disease, Ulcerative Colitis Formycon Income Position Target Market 2024 ● 2023 & 2024: Milestone payments in total of € 60m received USD 10.4 billion ● 2024: One time r
Slide 15: Eylea Biosimilar FYB203 – approved in US, EU and UK
Eylea® Biosimilar FYB203 – approved in US, EU and UK FYB203/aflibercept waiting in the wings Growth drivers ● Commercial Partnerships ● International Approvals ● Preparing Supply Chain in Accordance with IP Landscape FYB203 approved Eylea® is a registered trademark of Regeneron Pharmaceuticals Inc.
Slide 16: FYB203 – Eylea Biosimilar approved in US and EU
FYB203 – Eylea® Biosimilar approved in US and EU Eylea® is a registered trademark of Regeneron Pharmaceuticals Inc. AHZANTIVE® is a registered trademark of Klinge Biopharma GmbH Approved Targeted Reference Indications Formycon Income Position Neovascular AMD1, DME2, mCNV3, RVO4 ● Mid-single to low-d
Slide 17: FYB206 – Keytruda Biosimilar Candidate in the leading group
FYB206 – Keytruda® Biosimilar Candidate in the leading group Achievements and next important Milestones ● Clinical Phase I trial “Dahlia” started in June 2024 investigating the PK equivalence as part of a preventive therapy for patients Targeted Reference Indications who have had a malignant melanom
Slide 18: Outlook for 2025 – the next operational and commercial milestones
Outlook for 2025 – the next operational and commercial milestones are coming soon Approval of Approval of Commercial Launch Approval of Approval of Stelara® Biosimilar Stelara® Biosimilar of Stelara® Biosimilar Eylea® Biosimilar Lucentis® Biosimilar FYB202/Otulfi® in FYB202/Otulfi® in FYB202/Otulfi®
Slide 19: Solid financial Performance as expected
Solid financial Performance as expected Guidance Adjusted Working Guidance 2025 Revenue EBITDA 2024 EBITDA Capital Revenue: 55 to 65 -25 to -15 -5 to +5 35 to 45 ● Revenues expected at 2024 level ● Development recharges continue decreasing by approx. 50% € million € million € million € million ● FYB
Slide 20: Formycon – uplisted to Prime Standard and Part of the SDAX and the TecDAX
Formycon – uplisted to Prime Standard and Part of the SDAX and the TecDAX − Market Segment: Frankfurt Stock Exchange Shareholder Structure **per definition of Deutsche Börse Regulated Market (Prime Standard) 24.04 % Santo Holding (Deutschland) GmbH 13.25 % Wpart GmbH, Wen.Co Invest GmbH, Peter Wende
Slide 21: Fully focused pure-play Biosimilar Company
Fully focused pure-play Biosimilar Company WE HAVE all ingredients to WE ACT in a highly WE CREATED WE ARE entering the next successfully develop and attractive market a strong Platform with stage of the Formycon commercialize a growing track record Growth Story pipeline 21 Formycon AG // The Biosim
Slide 22: Formycon AG
Formycon AG Formycon AG Fraunhoferstr. 15 82152 Planegg-Martinsried Germany + 49 89 864 667 100 info@formycon.com www.formycon.com 22 Formycon AG Formycon AG // The Biosimilar Experts